Get the Stockscreener App
0.7971
0.37%
-0.003
After Hours:
.81
0.0129
+1.62%
Pds Biotechnology Corp stock is traded at $0.7971, with a volume of 3.82M.
It is down -0.37% in the last 24 hours and up +259.86% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
See More
Previous Close:
$0.8001
Open:
$0.804
24h Volume:
3.82M
Relative Volume:
0.19
Market Cap:
$57.77M
Revenue:
-
Net Income/Loss:
$-33.36M
P/E Ratio:
-1.1886
EPS:
-0.6706
Net Cash Flow:
$-23.09M
1W Performance:
-1.04%
1M Performance:
+259.86%
6M Performance:
+25.59%
1Y Performance:
-22.61%
1-Day Range:
$0.7805
$0.822
1-Week Range:
$0.75
$0.995
52-Week Range:
$0.1952
$1.55
Pds Biotechnology Corp Stock (PDSB) Company Profile
Name
Pds Biotechnology Corp
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.7971 | 57.77M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corp Stock (PDSB) Latest News
PDS Biotechnology Corporation (PDSB) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - cnn.com
PDS Biotechnology (NASDAQ: PDSB) Announces Phase 2 VERSATILE-002 Trial Results with 39.3-Month Median Survival - Kalkine Media
PDS Biotech reports 39.3-month survival data for HPV16 therapy By Investing.com - Investing.com Australia
PDS Biotech’s PDS0101 Shows 39.3-Month Median Survival in JAMA Oncology Publication - Minichart
PDS Biotech reports 39.3-month survival data for HPV16 therapy - Investing.com
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology - manilatimes.net
A head-and-neck cancer trial reported 39.3 months of median survival - Stock Titan
Patrick Soon-Shiong Secures Board Seat at PDS Biotechnology with 19.9% Stake - TradingView
PDS Biotechnology gets 19.9% Nant Capital stake | PDSB SEC FilingForm SCHEDULE 13D - Stock Titan
PDS Biotechnology updates corporate presentation highlighting PDS0301 clinical data and financing - tradingview.com
Patrick Soon-Shiong backs PDS Biotechnology (NASDAQ: PDSB) as cancer drugs move toward Phase 3 - Stock Titan
PDS Biotechnology Corporation (PDSB) Options ChainYahoo Finance - Yahoo! Finance Canada
PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny - Yahoo Finance
PullBack Stocks PDSB, PRSO, IGC, RETO: Who Breaks First? - FinancialContent
PDS Biotech Stock Surges Tuesday: What's Driving the Action? - Benzinga
PDS Biotechnology jumps as investors react to PIPE closing and Patrick Soon-Shiong tie-up - Quiver Quantitative
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
PDS Biotechnology Closes $11.3 Million Initial PIPE Tranche Led by Nant Capital - Minichart
PDS Biotechnology Retires Debt and Secures New Financing - TipRanks
PDS Biotechnology Retires Yorkville $6M Note Early With $4.6M Redemption - TradingView
PDS Biotech Raises $11.3 Million in Initial PIPE Led by Patrick Soon-Shiong - citybiz
PDS Biotechnology Raises $11.3 Million in Initial Closing of PIPE Led by Nant Capital; Dr. Soon-Shiong Joins Board - quiverquant.com
Weekly Recap: Up to $22.55M PIPE and HC Wainwright cuts price target to $5 - TradingView
PDS Biotechnology Market Sentiment - Benzinga España
Most Active Stocks on September 8: PDS Biotech, Green Circle, Mobix Labs, Intel and Nokia Lead Volume - ChartMill
Curious about the most active stocks on Tuesday? - ChartMill
PDS Biotech soars as it announces up to $22.55 million financing - thepharmaletter.com
PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure - Quiver Quantitative
PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC - AllSci
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August - Benzinga
PDS Biotechnology Announces PIPE Financing and Strategic Alignment - TipRanks
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com Canada
Phase 3 trial plan could unlock $11M more for PDS Biotechnology (NASDAQ: PDSB) - Stock Titan
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks - marketscreener.com
80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment - Stock Titan
PDS Biotechnology’s Phase 3 Head and Neck Cancer Trial Termination: What It Means for Investors - TipRanks
PDS Biotech’s Lender Gets 100% of New Non-ATM Equity Cash - TechStock²
PDSB News | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Amends $6 Million Promissory Note, Tightening Repayment With YA II PN - TradingView
PDS Biotechnology (Nasdaq: PDSB) changes terms on a $6M loan - Stock Titan
Stephan Toutain removed as COO at PDS Biotechnology - TradingView
PDS Biotechnology (PDSB) to shed 36% of staff and part ways with COO - Stock Titan
PDS Biotechnology Corp (NASDAQ: PDSB) Share Price, PDSB Stock News, PDSB Share Price & Updates - Kalkine
Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com Nigeria
PDS Biotechnology announces CFO resignation and interim appointments - Investing.com
PDS Biotechnology CFO Lars Boesgaard to Resign; Janetta Trochimiuk and Frank Bedu-Addo Appointed Interim Officers - TradingView
PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs - Stock Titan
Weekly Recap: PDS0301 Phase 2 results and Q2 adjusted loss $0.18 - TradingView
PDS Biotechnology shareholders approve charter amendment and director elections - Investing.com
Form 8K PDS Biotechnology Corp For: 14 August By Investing.com - Investing.com Nigeria
Pds Biotechnology Corp Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):